Jazz PharmaceuticalsJAZZ
JAZZ
About: Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Employees: 2,800
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
168% more call options, than puts
Call options by funds: $66.4M | Put options by funds: $24.7M
87% more first-time investments, than exits
New positions opened: 99 | Existing positions closed: 53
42% more repeat investments, than reductions
Existing positions increased: 216 | Existing positions reduced: 152
7% more funds holding
Funds holding: 502 [Q4 2024] → 539 (+37) [Q1 2025]
0% more capital invested
Capital invested by funds: $7.26B [Q4 2024] → $7.29B (+$31.2M) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 10 [Q4 2024] → 10 (+0) [Q1 2025]
0.84% less ownership
Funds ownership: 97.61% [Q4 2024] → 96.77% (-0.84%) [Q1 2025]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$147
35%
upside
Avg. target
$168
55%
upside
High target
$202
86%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Needham Ami Fadia | 86%upside $202 | Buy Reiterated | 11 Jun 2025 |
Baird Joel Beatty | 43%upside $155 | Outperform Maintained | 7 May 2025 |
RBC Capital Gregory Renza | 59%upside $172 | Outperform Maintained | 7 May 2025 |
Piper Sandler David Amsellem | 35%upside $147 | Overweight Reiterated | 7 May 2025 |
Morgan Stanley Jeffrey Hung | 53%upside $166 | Overweight Maintained | 7 May 2025 |
Financial journalist opinion
Based on 8 articles about JAZZ published over the past 30 days
Neutral
PRNewsWire
4 days ago
Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer
Target Action (PDUFA) Date set for October 7, 2025 Application based on data from IMforte, the first Phase 3 trial demonstrating statistically significant and clinically meaningful improvements in both progression-free and overall survival in the ES-SCLC first-line maintenance setting Jazz to host investor webcast on Tuesday, June 10 at 4:30 p.m. EDT / 9:30 p.m.
Neutral
PRNewsWire
5 days ago
Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025
First presentation of the Phase 4 XYLO switch study reports blood pressure reductions in patients with narcolepsy when switching from twice-nightly high- to low-sodium oxybate Novel intermediate analysis from the DUET trial cohort of patients taking >9 grams evaluated safety and changes in daytime sleepiness in adults with narcolepsy taking Xywav dosages of 9-12 grams per night For U.S. media and investors only DUBLIN , June 9, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced late-breaking Phase 4 data evaluating treatment benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in people with narcolepsy. These results are two of Jazz's four late-breaking abstracts presented today as oral presentations at SLEEP 2025.
Positive
Zacks Investment Research
1 week ago
Why Is Jazz (JAZZ) Up 7.9% Since Last Earnings Report?
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
Neutral
PRNewsWire
1 week ago
Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
First-line maintenance combination therapy reduced the risk of disease progression or death by 46%, with a median overall survival of 13.2 months vs 10.6 months for atezolizumab alone from the point of randomization First Phase 3 study to demonstrate statistically significant and clinically meaningful improvements in both progression-free and overall survival in ES-SCLC first-line maintenance Results presented at the ASCO 2025 Annual Meeting and simultaneously published in The Lancet Jazz to host investor webcast on Tuesday, June 10 to review Zepzelca data For U.S. media and investors only DUBLIN , June 2, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive results from the Phase 3 IMforte study of Zepzelca® (lurbinectedin) in combination with atezolizumab (Tecentriq®) as a first-line maintenance treatment for people with extensive-stage small cell lung cancer (ES-SCLC), following induction therapy with carboplatin, etoposide and atezolizumab. The study met both primary endpoints, demonstrating statistically significant improvements in progression-free survival (PFS) and overall survival (OS) compared to atezolizumab alone.
Neutral
PRNewsWire
1 week ago
Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025
Phase 2 trial results continue to show clinically meaningful efficacy and durable responses, including 36.5-month median overall survival after four years of follow-up, with a manageable safety profile Findings presented today at ASCO 2025 and concurrently published in The Lancet Oncology For U.S. media and investors only DUBLIN , June 2, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced long-term data, including the first report of median overall survival (OS) from the Phase 2 trial evaluating Ziihera® (zanidatamab-hrii), a dual HER2-targeted bispecific antibody, in combination with chemotherapy for the investigational use in first-line HER2-positive (IHC 3+ or IHC 2+/FISH+) locally advanced nonresectable gastroesophageal adenocarcinoma (mGEA). The data were featured as a rapid oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, and the results were concurrently published in The Lancet Oncology.
Neutral
PRNewsWire
2 weeks ago
Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025
Nineteen abstracts, including eleven late-breaking abstracts, underscore Jazz's leadership and extensive research in sleep medicine, and ongoing commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia For U.S. media and investors only DUBLIN , May 29, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that nineteen abstracts, including eleven late-breaking abstracts will be presented at SLEEP 2025, the 39th annual meeting of the Associated Professional Sleep Societies (APSS) being held June 8-11, 2025, in Seattle. Research to be presented at the meeting include dual late-breaking poster and oral presentations, which highlight the extensive Phase 4 data evaluating the effectiveness of low-sodium oxybate, Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in patients with narcolepsy and idiopathic hypersomnia (IH).
Neutral
PRNewsWire
3 weeks ago
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
DUBLIN , May 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Company management will participate in the following investor conferences: Jefferies Global Healthcare Conference on Thursday, June 5, 2025 Fireside chat at 6:55 a.m. PDT / 9:55 a.m.
Neutral
Seeking Alpha
3 weeks ago
Jazz Pharmaceuticals: One Step Forward, One Back
Jazz took a step forward with the Chimerix acquisition that should further diversify its revenue base. The oxybate business experienced a setback when Avadel won the appeal that allows Lumryz to compete with Jazz's Xywav in idiopathic hypersomnia. There are three potential catalysts for the oncology business in the second half of the year that should translate to a revenue growth inflection point in 2026.
Positive
Zacks Investment Research
1 month ago
Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects
Evaluate Jazz's (JAZZ) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Negative
Zacks Investment Research
1 month ago
JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook
Jazz reports dismal first-quarter results. The company revises its 2025 EPS guidance to account for the recently completed Chimerix acquisition.
Charts implemented using Lightweight Charts™